Loading...
XKRX099190
Market cap285mUSD
Dec 27, Last price  
15,260.00KRW
1D
-2.18%
1Q
-14.84%
Jan 2017
3.81%
IPO
74.07%
Name

I Sens Inc

Chart & Performance

D1W1MN
XKRX:099190 chart
P/E
113.03
P/S
1.58
EPS
135.00
Div Yield, %
1.15%
Shrs. gr., 5y
0.18%
Rev. gr., 5y
8.91%
Revenues
265.12b
+0.11%
66,549,429,80082,862,589,51095,608,058,130101,920,703,199132,468,196,930156,963,800,842172,996,578,932189,844,257,361203,707,640,796232,934,791,026264,837,131,104265,120,260,370
Net income
3.71b
-77.02%
8,744,729,07018,641,928,16014,466,160,94014,715,903,02917,560,919,12115,730,466,07522,619,253,76923,425,871,70826,838,557,96025,451,013,45016,138,019,3103,709,063,090
CFO
13.05b
+96.06%
5,102,430,35016,190,153,21017,845,210,70020,400,604,58912,065,120,82622,247,810,24419,508,172,13937,950,911,70434,614,942,25517,223,810,7396,653,468,56313,045,086,880
Dividend
Dec 27, 2023175 KRW/sh
Earnings
Feb 11, 2025

Profile

i-SENS, Inc. provides diagnostic biosensors in South Korea. The company offers point of care testing devices, such as HbA1c, blood gas, electrolyte, and PT/INR analyzers; CareSens blood glucose monitoring systems; and lancing and other ancillary devices, as well as diabetes management services. It exports its products to approximately 110 countries, including the United States, Japan, and Europe. The company was founded in 2000 and is headquartered in Seoul, South Korea.
URL
https://i-sens.co.kr/
IPO date
Jan 30, 2013
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
265,120,260
0.11%
264,837,131
13.70%
232,934,791
14.35%
Cost of revenue
212,986,806
211,888,423
172,488,618
Unusual Expense (Income)
NOPBT
52,133,454
52,948,708
60,446,173
NOPBT Margin
19.66%
19.99%
25.95%
Operating Taxes
2,728,418
3,245,791
5,590,039
Tax Rate
5.23%
6.13%
9.25%
NOPAT
49,405,036
49,702,917
54,856,134
Net income
3,709,063
-77.02%
16,138,019
-36.59%
25,451,013
-5.17%
Dividends
(4,806,037)
(4,078,518)
(3,398,765)
Dividend yield
0.61%
0.90%
0.83%
Proceeds from repurchase of equity
330,000
3,808,308
BB yield
-0.04%
-0.84%
Debt
Debt current
95,134,961
34,791,726
5,634,251
Long-term debt
53,630,501
66,061,169
95,238,648
Deferred revenue
1
2,377,157
1,002,951
Other long-term liabilities
4,498,473
2,318,538
6,321,586
Net debt
64,921,323
(1,628,767)
(29,792,316)
Cash flow
Cash from operating activities
13,045,087
6,653,469
17,223,811
CAPEX
(44,158,366)
(25,996,184)
(48,193,489)
Cash from investing activities
(63,783,114)
17,189,946
(47,204,273)
Cash from financing activities
34,940,764
(9,907,978)
45,888,931
FCF
11,621,842
10,767,350
(33,085,734)
Balance
Cash
54,976,089
72,520,781
100,670,739
Long term investments
28,868,050
29,960,882
29,994,477
Excess cash
70,588,126
89,239,806
119,018,477
Stockholders' equity
262,004,027
258,211,735
241,535,543
Invested Capital
381,195,989
314,462,449
268,836,535
ROIC
14.20%
17.04%
24.17%
ROCE
11.47%
13.06%
15.41%
EV
Common stock shares outstanding
27,703
27,463
27,237
Price
28,600.00
73.86%
16,450.00
8.76%
15,125.00
0.83%
Market cap
792,319,585
75.38%
451,767,222
9.66%
411,962,892
0.95%
EV
876,385,700
469,084,743
398,578,853
EBITDA
65,699,129
65,002,267
71,340,568
EV/EBITDA
13.34
7.22
5.59
Interest
2,979,341
1,870,081
856,239
Interest/NOPBT
5.71%
3.53%
1.42%